TrialThe oncologist2022

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

Robert Q Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.